FDA Inspection 1019839 — Hongfe Zhang
The FDA completed an inspection of Hongfe Zhang on Jun 16, 2017 in Beijing. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 16, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Beijing (China)
Additional details
Clinical Investigator (CI)